DETECÇÃO E GENOTIPAGEM DE HPV EM CARCINOMAS DE VULVA E DE VAGINA.

Abstract

This study evaluated the sociodemographic and clinicopathological aspects of patients with cancer of the vulva and the vagina diagnosed in Araújo Jorge Hospital, Goiânia - GO as well as the prevalence of HPV and HPV16 and 18 genotypes in these tumors. The sample consisted of paraffin embedded samples from 57 patients with primary invasive vulvar cancer and 20 patients with primary invasive cancer of the vagina. The HPV detection was made by polymerase chain reaction (PCR) with SPF (short PCR fragment) 1-2 primers and the HPV 16 and 18 genotyping was performed with primers designed to detect these two genotypes. The results were analyzed by Fisher s exact test. The prevalence of HPV in vulvar cancer samples was 89%. The HPV16 genotype was detected in 42% of positive cases and HPV18 in 24%. The HPV prevalence in vaginal cancer samples was 90%. Among these, 56% were infections by HPV16 and HPV18 by 18%. Over 70% of patients with vulvar and vaginal cancer and positive for HPV detection were over 50 years. Statistical analyzes of the data showed significance of smoking for cancer of the vulva (p = 0.0110). A relationship between lymph node metastasis and cancer of the vulva was also observed (p = 0.0304). A better prognosis for patients with vaginal cancer HPV positive was found (p = 0.0158). A relationship between the degree of tumor differentiation and the presence of HPV in patients with cancer of the vulva was suggested (p = 0.0541). Based on the results presented, it is estimated that the HPV vaccine could have prevented 58% of cases of vulvar cancer and 65% of cases of vaginal cancer of the sample investigated.